Jazz Pharmaceuticals plc Q3 2025 Earnings Recap

JAZZ Q3 2025 November 7, 2025

Get alerts when JAZZ reports next quarter

Jazz Pharmaceuticals achieved record revenues of over $1.1 billion in Q3 2025, fueled by strong sales across its product portfolio and two significant FDA approvals, paving the way for continued growth and strategic advancements.

Earnings Per Share Beat

$8.13 vs $5.95 est.

+36.6% surprise

Revenue Beat

1126107000 vs 1111117109 est.

+1.3% surprise

Market Reaction

1-Day -2.16%

5-Day +1.98%

30-Day +24.36%

See JAZZ alongside your other holdings

Add to your portfolio — free

Key Takeaways

Secured FDA approvals for Modeyso and Zepzelca, expanding treatment options for severe conditions.
Strong commercial performance driven by Xywav's 11% year-over-year growth, contributing $431 million in net sales.
Narrowed 2025 revenue guidance to $4.175 billion - $4.275 billion, reflecting confidence in future performance.
Completed settlements in Xyrem antitrust litigation, allowing focus on strategic execution and shareholder value.
Strengthened the pipeline with the Saniona licensing agreement for a promising epilepsy candidate, SAN2355.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit JAZZ on AllInvestView.

Next Q1 2026